In this study, the SLN formulation of DXMS-Pal (DXMS-Pal-SLNs) was developed and evaluated in reducing the secretion of pro-inflammatory cytokines, namely TNF-α and IL-6, mainly by alveolar macrophages for pneumonia-associated inflammation treatment. This evidence concerns the gene IL6 and pneumonia.